Please login to the form below

Not currently logged in
Email:
Password:

John LaMattina joins Frequency Therapeutics in advisory role

The ex-Pfizer R&D head will sit on its Scientific Advisory Board

John LaMattinaFrequency Therapeutics has appointed John LaMattina as its senior advisor to the CEO in a role that will see him focus on assisting its development of a treatment for hearing loss, serving on the firm’s Scientific Advisory Board.

LaMattina was previously president of Pfizer’s Global Research and Development department and senior vice president and spent 30 years at the pharma company.

He said: “It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss.

“The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new-disease modifying therapies for hearing and other areas throughout the body.”

Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.

David Lucchino, president, co-founder and CEO of Frequences Therapeutics, said: “As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise.

"John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”

4th April 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics